BACKGROUND: The correlation between DPYD*9A (c.85T>C) genotype and dihydropyrimidine dehydrogenase (DPD) deficiency clinical phenotype is controversial. Reference laboratories either did not perform DPYD*9A genotyping or have stopped DPYD*9A genotyping and limited genotyping to high-risk variants (DPYD*2A, DPYD*13 and DPYD*9B) only. This study explored DPYD*9A genotype and clinical phenotype correlation in patients with gastrointestinal (GI) malignancies treated with fluoropyrimidines. METHODS: Between 2011 and 2017, 67 patients with GI malignancies were genotyped for DPYD variants. Fluoropyrimidines-associated toxicity was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 3.0). Fisher's exact test was used for statistical analysis. RESULTS: DPYD variants were identified in 17 out of 67 (25%) patients. One patient was homozygous for DPYD*9A variant and one patient was double heterozygous for DPYD*9A and DPYD*9B variants. In patients with identified DPYD variants, 13/17 (76%) patients had DPYD*9A variant, 3/17 (18%) patients had DPYD*2A variant and 2/17 (12%) patient had DPYD*9B variant. Only patients genotyped prior to 2015 were genotyped for DPYD*9A variant (N=28). Of those, 13/28 patients (46%) had DPYD*9A variant. Grade 3-4 diarrhea was associated with DPYD*9A variant in patients treated with full dose fluoropyrimidines (P=0.0055). CONCLUSIONS: In our cohort, DPYD*9A variant was the most common diagnosed variant. The correlation between DPYD*9A genotype and DPD deficiency in clinical phenotype was noticeable in patients who received full dose fluoropyrimidines as they all experienced grade 3-4 toxicities (diarrhea).
BACKGROUND: The correlation between DPYD*9A (c.85T>C) genotype and dihydropyrimidine dehydrogenase (DPD) deficiency clinical phenotype is controversial. Reference laboratories either did not perform DPYD*9A genotyping or have stopped DPYD*9A genotyping and limited genotyping to high-risk variants (DPYD*2A, DPYD*13 and DPYD*9B) only. This study explored DPYD*9A genotype and clinical phenotype correlation in patients with gastrointestinal (GI) malignancies treated with fluoropyrimidines. METHODS: Between 2011 and 2017, 67 patients with GI malignancies were genotyped for DPYD variants. Fluoropyrimidines-associated toxicity was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 3.0). Fisher's exact test was used for statistical analysis. RESULTS: DPYD variants were identified in 17 out of 67 (25%) patients. One patient was homozygous for DPYD*9A variant and one patient was double heterozygous for DPYD*9A and DPYD*9B variants. In patients with identified DPYD variants, 13/17 (76%) patients had DPYD*9A variant, 3/17 (18%) patients had DPYD*2A variant and 2/17 (12%) patient had DPYD*9B variant. Only patients genotyped prior to 2015 were genotyped for DPYD*9A variant (N=28). Of those, 13/28 patients (46%) had DPYD*9A variant. Grade 3-4 diarrhea was associated with DPYD*9A variant in patients treated with full dose fluoropyrimidines (P=0.0055). CONCLUSIONS: In our cohort, DPYD*9A variant was the most common diagnosed variant. The correlation between DPYD*9A genotype and DPD deficiency in clinical phenotype was noticeable in patients who received full dose fluoropyrimidines as they all experienced grade 3-4 toxicities (diarrhea).
Authors: E Van Cutsem; C Twelves; J Cassidy; D Allman; E Bajetta; M Boyer; R Bugat; M Findlay; S Frings; M Jahn; J McKendrick; B Osterwalder; G Perez-Manga; R Rosso; P Rougier; W H Schmiegel; J F Seitz; P Thompson; J M Vieitez; C Weitzel; P Harper Journal: J Clin Oncol Date: 2001-11-01 Impact factor: 44.544
Authors: Lori Kay Mattison; Jeanne Fourie; Renee A Desmond; Anil Modak; Muhammad Wasif Saif; Robert B Diasio Journal: Clin Cancer Res Date: 2006-09-15 Impact factor: 12.531
Authors: M Joerger; A D R Huitema; H Boot; A Cats; V D Doodeman; P H M Smits; L Vainchtein; H Rosing; I Meijerman; M Zueger; D Meulendijks; T D Cerny; J H Beijnen; J H M Schellens Journal: Cancer Chemother Pharmacol Date: 2015-02-13 Impact factor: 3.333
Authors: Ursula Amstutz; Steven M Offer; Johanna Sistonen; Markus Joerger; Robert B Diasio; Carlo R Largiadèr Journal: Clin Cancer Res Date: 2015-02-05 Impact factor: 12.531
Authors: Matthias Schwab; Ulrich M Zanger; Claudia Marx; Elke Schaeffeler; Kathrin Klein; Jürgen Dippon; Reinhold Kerb; Julia Blievernicht; Joachim Fischer; Ute Hofmann; Carsten Bokemeyer; Michel Eichelbaum Journal: J Clin Oncol Date: 2008-02-25 Impact factor: 44.544
Authors: Steven M Offer; Croix C Fossum; Natalie J Wegner; Alexander J Stuflesser; Gabriel L Butterfield; Robert B Diasio Journal: Cancer Res Date: 2014-03-19 Impact factor: 12.701
Authors: A Loganayagam; M Arenas Hernandez; A Corrigan; L Fairbanks; C M Lewis; P Harper; N Maisey; P Ross; J D Sanderson; A M Marinaki Journal: Br J Cancer Date: 2013-06-04 Impact factor: 7.640
Authors: Cassandra White; Rodney J Scott; Christine Paul; Andrew Ziolkowski; David Mossman; Stephen Ackland Journal: Pharmgenomics Pers Med Date: 2021-12-09
Authors: Seid Hamzic; Dominic Schärer; Steven M Offer; Didier Meulendijks; Christos Nakas; Robert B Diasio; Stefano Fontana; Marc Wehrli; Stefan Schürch; Ursula Amstutz; Carlo R Largiadèr Journal: Br J Clin Pharmacol Date: 2021-03-30 Impact factor: 4.335